Disrupting PD-L1 UFMylation through the depletion of UFL1 or UFM1, or by defective UFMylation of PD-L1 itself, stabilized PD-L1 in various human and murine cancer cell lines, which impair antitumor immunity both in vitro and in vivo. This evidence concerns the gene CD274 and cancer.